Indifferent Diagnosis- The Health of BioPharma in 2025

By Frank F. Dolan
Listen with Sir Michael Caine™ and 1,000+ voices
Length2h 35m

About this audiobook

Indifferent Diagnosis: The Health of BioPharma in 2025 is your inside pass to an industry running at two speeds—record-breaking M&A on one end, widespread cash-burn triage on the other. Veteran strategist Frank Dolan unpacks why 40 % of public biotechs are months from insolvency while giants like Pfizer and Novartis spend billions on de-risked assets; how AI, CRISPR, and next-gen delivery tech are redrawing drug-discovery maps; and where regulatory, demographic, and private-equity cross-currents will push the market next. Packed with hard data, boardroom stories, and survival playbooks, this audiobook arms executives, investors, and scientists with the context—and contrarian edge—needed to navigate 2025’s most volatile sector.

Audiobook details

Rating★★★★★ 5.0 (3)
GenreBusiness and Economics
Length2 hrs 35 mins
Narrated byListen with 1,000+ voices
FormateBook with Audio
Publish dateJun 25, 2025
LanguageEnglish

Table of contents

1Introduction
2Chapter 1: The State of Biopharma in 2025
3Chapter 2: M&A Activity: A Boon and a Burden
4Chapter 3: Understanding Financial Distress in Biotech Companies
5Chapter 4: The IPO Market: Is the Opportunity Shrinking?
Mostrar todos os capítulos
6Chapter 5: Exploring Alternative Financing Strategies
7Chapter 6: The Rise of Private Equity in the Biopharmaceutical Industry
8Chapter 7: Long-Term Growth Drivers: Key Factors Shaping Future Success
9Chapter 8: Regulatory Challenges and Their Impact on the Industry
10Chapter 9: Investor Sentiment – Navigating Cautious Optimism
11Chapter 10: Building Strategic Partnerships and Collaborations
12Chapter 11: Therapeutic Focus Areas in 2025
13Chapter 12: The Role of Technology in Driving Innovation
14Chapter 13: Regional Trends and Cross-Border Activities
15Chapter 14: Understanding Risk Factors and Managing Market Volatility
16Chapter 15: The Future of Drug Development and Innovation
17Chapter 16: The Impact of Demographic Changes on the Market
18Chapter 17: Understanding the Competitive Landscape
19Chapter 18: The Evolution of Business Models
20Chapter 19: Lessons from 2025: Insights and Predictions for the Future
21Preparing for Future Market Changes
Never Split the DifferenceChris Voss, Tahl Raz8h 7m4.4 (277.7K)$26 · $0.00
The Intelligent Investor Rev Ed.Benjamin Graham17h 48m4.3 (191.5K)$40 · $0.00
The Hard Thing About Hard ThingsBen Horowitz7h 57m4.2 (134.3K)$26 · $0.00
Boundaries for LeadersHenry Cloud7h 36m4.3 (3.6K)$26 · $0.00
The Secret Door to SuccessFlorence Scovel Shinn2h 25m4.5 (2.1K)$1.20 · $0.00
This Is Going to HurtAdam Kay5h 47m4.4 (444.7K)$24 · $0.00
Big TrustShadé Zahrai, Fayçal Sekkouah8h 36m4.6 (406)$26 · $0.00
The Intelligent Investor Third EditionBenjamin Graham, Jason Zweig20h4.4 (156.6K)$46 · $0.00
Bottle of LiesKatherine Eban14h 25m4.4 (12K)$33 · $0.00
The Antiracist Business BookTrudi Lebrón6h 10m4.6 (275)$17 · $0.00
The FormulaJoshua Robinson, Jonathan Clegg10h 41m4.4 (6.9K)$29 · $0.00
Let Them LeadJohn U. Bacon7h 10m4.5 (1.4K)$24 · $0.00
Secrets of the Millionaire MindT. Harv Eker5h 11m4.4 (301.4K)$24 · $0.00
The Person You Mean to BeDolly Chugh9h 6m4.4 (7.2K)$29 · $0.00
BoundlessNick Kostov, Sean McLain9h 17m4.5 (1.1K)$29 · $0.00
Everyday DharmaSuneel Gupta5h 2m4.5 (761)$20 · $0.00
Let's Talk Mutual FundsMonika Halan7h 5m4.4 (2.4K)$16 · $0.00
Secret PowerDwight Lyman Moody3h 7m4.4 (1.4K)$1.20 · $0.00
The Law of Success in Sixteen LessonsNapoleon Hill2h 39m4.4 (17.2K)$2 · $0.00
Barbarians at the GateBryan Burrough, John Helyar3h 3m4.4 (52.7K)$18 · $0.00

You may also like